KRAS G12D protein screening for pancreatic cancer clinical trials using an AlGaN/GaN high electron mobility transistor biosensor
Sheng-Ting Hung (1), Cheng Yan Lee (1), Chen-Yu Lien (1), Cheng-Hsuan Chan (1), Ya-Han Yang (2), Quark Yungsung Chen (3, 4), Kuang-Hung Cheng (5), Kung-Kai Kuo (2, 6), Li-Wei Tu (1), Ching-Wen Chang (7) ((1) Department of Physics, National Sun Yat-sen University, Kaohsiung
TL;DR
This study demonstrates the effectiveness of an AlGaN/GaN HEMT biosensor in detecting KRAS G12D protein, showing promise for early pancreatic cancer diagnosis through clinical trial screening.
Contribution
First application of AlGaN/GaN HEMT biosensor for KRAS G12D detection in pancreatic cancer clinical trials, highlighting its potential for early diagnosis.
Findings
PDAC patients show higher resistance change ratios than healthy donors.
The biosensor effectively distinguishes between patients and healthy individuals.
Results suggest potential for early pancreatic cancer detection.
Abstract
Clinical trials screening KRAS G12D protein for 30 pancreatic ductal adenocarcinoma (PDAC) patients and 30 healthy donors were conducted utilizing an AlGaN/GaN high electron mobility transistor (HEMT) biosensor. All resistance change ratios of PDAC patients are higher than the standard deviation above the mean resistance change ratio obtained from all healthy donors. The results demonstrate the effectiveness of the HEMT biosensor and reveal its potential for early detection of pancreatic cancer with KRAS G12D protein screening.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.